Effects of Optison® on pulmonary gas exchange and hemodynamics

Yoshiki Yamaya, Kyuichi Niizeki, Jeannie Kim, Pauline L Entin, Harrieth Wagner, Peter D. Wagner

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Optison® is a contrast-enhancing agent used in myocardial contrast echocardiography. It consists of small albumin spherules (approximately 4-μm diameter) containing a fluorocarbon gas, octafluoropropane. It is injected IV and, thus, may cause pulmonary manifestations of microembolism. To determine if any such effects do occur, we injected sequential doses of 1, then 3 and then 5 mL Optison® IV into 25 kg anesthetized dogs, and measured pulmonary hemodynamic and gas exchange variables frequently for 30 min after each dose. This was done in both 6 healthy and 6 pulmonary hypertensive animals, the latter produced by acute IV injection of 676-μm diameter polystyrene beads, raising pulmonary artery pressure from normal (15 mmHg) to 33 mmHg. Optison®-injected animals were compared with albumin-injected controls. Two animals developed severe hypotension in response to albumin and could not be used. Lung compliance and wet/dry weight ratio were unaffected by Optison® and no effects on gas exchange were seen at any dose or time in either group of dogs. In the healthy group, there was slight (1 mmHg per mL Optison®), transient and delayed pulmonary hypertension without change in cardiac output, suggesting a vasoconstrictor rather than mechanical basis for these small effects. No such changes occurred in the pulmonary hypertensive group. These results imply that usual human doses of Optison® (0.5 mL) will produce no significant hemodynamic or gas exchange effects in either healthy or pulmonary hypertensive dogs.

Original languageEnglish (US)
Pages (from-to)1005-1013
Number of pages9
JournalUltrasound in Medicine and Biology
Volume28
Issue number8
DOIs
StatePublished - Aug 2002
Externally publishedYes

Fingerprint

Pulmonary Gas Exchange
gas exchange
hemodynamics
dogs
Hemodynamics
albumins
animals
dosage
Albumins
Lung
hypotension
perflutren
Gases
cardiac output
Dogs
spherules
hypertension
echocardiography
fluorocarbons
arteries

Keywords

  • Hypoxemia
  • Myocardial echocardiography
  • Perfusion inequality
  • Pulmonary embolism
  • Pulmonary vascular resistance
  • Ventilation

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Effects of Optison® on pulmonary gas exchange and hemodynamics. / Yamaya, Yoshiki; Niizeki, Kyuichi; Kim, Jeannie; Entin, Pauline L; Wagner, Harrieth; Wagner, Peter D.

In: Ultrasound in Medicine and Biology, Vol. 28, No. 8, 08.2002, p. 1005-1013.

Research output: Contribution to journalArticle

Yamaya, Yoshiki ; Niizeki, Kyuichi ; Kim, Jeannie ; Entin, Pauline L ; Wagner, Harrieth ; Wagner, Peter D. / Effects of Optison® on pulmonary gas exchange and hemodynamics. In: Ultrasound in Medicine and Biology. 2002 ; Vol. 28, No. 8. pp. 1005-1013.
@article{0401a36483a84704a21eaaa03cf2c152,
title = "Effects of Optison{\circledR} on pulmonary gas exchange and hemodynamics",
abstract = "Optison{\circledR} is a contrast-enhancing agent used in myocardial contrast echocardiography. It consists of small albumin spherules (approximately 4-μm diameter) containing a fluorocarbon gas, octafluoropropane. It is injected IV and, thus, may cause pulmonary manifestations of microembolism. To determine if any such effects do occur, we injected sequential doses of 1, then 3 and then 5 mL Optison{\circledR} IV into 25 kg anesthetized dogs, and measured pulmonary hemodynamic and gas exchange variables frequently for 30 min after each dose. This was done in both 6 healthy and 6 pulmonary hypertensive animals, the latter produced by acute IV injection of 676-μm diameter polystyrene beads, raising pulmonary artery pressure from normal (15 mmHg) to 33 mmHg. Optison{\circledR}-injected animals were compared with albumin-injected controls. Two animals developed severe hypotension in response to albumin and could not be used. Lung compliance and wet/dry weight ratio were unaffected by Optison{\circledR} and no effects on gas exchange were seen at any dose or time in either group of dogs. In the healthy group, there was slight (1 mmHg per mL Optison{\circledR}), transient and delayed pulmonary hypertension without change in cardiac output, suggesting a vasoconstrictor rather than mechanical basis for these small effects. No such changes occurred in the pulmonary hypertensive group. These results imply that usual human doses of Optison{\circledR} (0.5 mL) will produce no significant hemodynamic or gas exchange effects in either healthy or pulmonary hypertensive dogs.",
keywords = "Hypoxemia, Myocardial echocardiography, Perfusion inequality, Pulmonary embolism, Pulmonary vascular resistance, Ventilation",
author = "Yoshiki Yamaya and Kyuichi Niizeki and Jeannie Kim and Entin, {Pauline L} and Harrieth Wagner and Wagner, {Peter D.}",
year = "2002",
month = "8",
doi = "10.1016/S0301-5629(02)00549-5",
language = "English (US)",
volume = "28",
pages = "1005--1013",
journal = "Ultrasound in Medicine and Biology",
issn = "0301-5629",
publisher = "Elsevier USA",
number = "8",

}

TY - JOUR

T1 - Effects of Optison® on pulmonary gas exchange and hemodynamics

AU - Yamaya, Yoshiki

AU - Niizeki, Kyuichi

AU - Kim, Jeannie

AU - Entin, Pauline L

AU - Wagner, Harrieth

AU - Wagner, Peter D.

PY - 2002/8

Y1 - 2002/8

N2 - Optison® is a contrast-enhancing agent used in myocardial contrast echocardiography. It consists of small albumin spherules (approximately 4-μm diameter) containing a fluorocarbon gas, octafluoropropane. It is injected IV and, thus, may cause pulmonary manifestations of microembolism. To determine if any such effects do occur, we injected sequential doses of 1, then 3 and then 5 mL Optison® IV into 25 kg anesthetized dogs, and measured pulmonary hemodynamic and gas exchange variables frequently for 30 min after each dose. This was done in both 6 healthy and 6 pulmonary hypertensive animals, the latter produced by acute IV injection of 676-μm diameter polystyrene beads, raising pulmonary artery pressure from normal (15 mmHg) to 33 mmHg. Optison®-injected animals were compared with albumin-injected controls. Two animals developed severe hypotension in response to albumin and could not be used. Lung compliance and wet/dry weight ratio were unaffected by Optison® and no effects on gas exchange were seen at any dose or time in either group of dogs. In the healthy group, there was slight (1 mmHg per mL Optison®), transient and delayed pulmonary hypertension without change in cardiac output, suggesting a vasoconstrictor rather than mechanical basis for these small effects. No such changes occurred in the pulmonary hypertensive group. These results imply that usual human doses of Optison® (0.5 mL) will produce no significant hemodynamic or gas exchange effects in either healthy or pulmonary hypertensive dogs.

AB - Optison® is a contrast-enhancing agent used in myocardial contrast echocardiography. It consists of small albumin spherules (approximately 4-μm diameter) containing a fluorocarbon gas, octafluoropropane. It is injected IV and, thus, may cause pulmonary manifestations of microembolism. To determine if any such effects do occur, we injected sequential doses of 1, then 3 and then 5 mL Optison® IV into 25 kg anesthetized dogs, and measured pulmonary hemodynamic and gas exchange variables frequently for 30 min after each dose. This was done in both 6 healthy and 6 pulmonary hypertensive animals, the latter produced by acute IV injection of 676-μm diameter polystyrene beads, raising pulmonary artery pressure from normal (15 mmHg) to 33 mmHg. Optison®-injected animals were compared with albumin-injected controls. Two animals developed severe hypotension in response to albumin and could not be used. Lung compliance and wet/dry weight ratio were unaffected by Optison® and no effects on gas exchange were seen at any dose or time in either group of dogs. In the healthy group, there was slight (1 mmHg per mL Optison®), transient and delayed pulmonary hypertension without change in cardiac output, suggesting a vasoconstrictor rather than mechanical basis for these small effects. No such changes occurred in the pulmonary hypertensive group. These results imply that usual human doses of Optison® (0.5 mL) will produce no significant hemodynamic or gas exchange effects in either healthy or pulmonary hypertensive dogs.

KW - Hypoxemia

KW - Myocardial echocardiography

KW - Perfusion inequality

KW - Pulmonary embolism

KW - Pulmonary vascular resistance

KW - Ventilation

UR - http://www.scopus.com/inward/record.url?scp=0036668763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036668763&partnerID=8YFLogxK

U2 - 10.1016/S0301-5629(02)00549-5

DO - 10.1016/S0301-5629(02)00549-5

M3 - Article

VL - 28

SP - 1005

EP - 1013

JO - Ultrasound in Medicine and Biology

JF - Ultrasound in Medicine and Biology

SN - 0301-5629

IS - 8

ER -